Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -1299.47% is 44% below its 5-year average of -899.92%, near the low end of its 5-year range (-1779.11%–-97.62%).
0.15% above its 12-month average of -1301.48%.
Reported quarterly EBITDA margin; no daily interpolation. Q4 FY2025 (2025-12-31): -1179.10%.
EBITDA MARGIN
-1299.47%
EBITDA MARGIN AVG TTM
-1301.48%
EBITDA MARGIN AVG 3Y
-1301.48%
EBITDA MARGIN AVG 5Y
-899.92%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+0.15%
CURRENT VS 3Y AVG
+0.15%
CURRENT VS 5Y AVG
-44.40%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Korro Bio, Inc.
Market Cap
$97.14M
EBITDA Margin
-1299.47%
TTM Avg
-1301.48%
3Y Avg
-1301.48%
5Y Avg
-899.92%
Market Cap
$96.58M
EBITDA Margin
5.05%
TTM Avg
6.33%
3Y Avg
5.80%
5Y Avg
5.80%
Market Cap
$94.72M
EBITDA Margin
-4034.35%
TTM Avg
-4034.35%
3Y Avg
-3775.34%
5Y Avg
-2903.14%
Market Cap
$102.75M
EBITDA Margin
-5221.43%
TTM Avg
-5221.43%
3Y Avg
-3887.65%
5Y Avg
-3386.47%
Market Cap
$103.14M
EBITDA Margin
28.85%
TTM Avg
28.85%
3Y Avg
28.85%
5Y Avg
28.85%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Korro Bio, Inc. (KRRO) | $97.14M | -1299.47% | -1301.48% | -1301.48% | -899.92% |
| PolyPid Ltd. (PYPD)vs › | $97.61M | N/A | N/A | N/A | N/A |
| Conexeu Sciences Inc. (CNXU)vs › | $97.94M | N/A | N/A | N/A | N/A |
| Park Dental Partners, Inc. Common Stock (PARK)vs › | $96.58M | 5.05% | 6.33% | 5.80% | 5.80% |
| OnKure Therapeutics, Inc. (OKUR)vs › | $98.41M | N/A | N/A | N/A | N/A |
| Milestone Pharmaceuticals Inc. (MIST)vs › | $94.72M | -4034.35% | -4034.35% | -3775.34% | -2903.14% |
| The Joint Corp. (JYNT)vs › | $101.36M | 1.47% | 3.45% | 8.31% | 9.97% |
| Anixa Biosciences, Inc. (ANIX)vs › | $102.75M | -5221.43% | -5221.43% | -3887.65% | -3386.47% |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $103.14M | 28.85% | 28.85% | 28.85% | 28.85% |
| Polaryx Therapeutics, Inc. Common Stock (PLYX)vs › | $104.18M | N/A | N/A | N/A | N/A |
Gross Margin
33.0%
EBITDA Margin
-1299.5%
Operating Margin
-1366.4%
Net Margin
-4477.1%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2025-12-31 | -1179.10% |
| 2025-09-30 | -1656.70% |
| 2025-06-30 | -1779.11% |
| 2025-03-31 | -933.14% |
| 2024-12-31 | -959.36% |
| 2021-06-30 | -174.44% |
| 2021-03-31 | -419.93% |
| 2020-12-31 | -97.62% |
| 2020-09-30 | -44.69% |
| 2020-06-30 | -68.83% |
| 2020-03-31 | -73.86% |
| 2019-12-31 | -133.00% |
| 2019-09-30 | -4.28% |
